DK0572537T3 - Cytokinnhibitorer - Google Patents

Cytokinnhibitorer

Info

Publication number
DK0572537T3
DK0572537T3 DK92907362T DK92907362T DK0572537T3 DK 0572537 T3 DK0572537 T3 DK 0572537T3 DK 92907362 T DK92907362 T DK 92907362T DK 92907362 T DK92907362 T DK 92907362T DK 0572537 T3 DK0572537 T3 DK 0572537T3
Authority
DK
Denmark
Prior art keywords
production
inhibiting
cytokine inhibitors
mammal
interleukin
Prior art date
Application number
DK92907362T
Other languages
English (en)
Inventor
Alison Mary Badger
Wanda Bernadette High
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Application granted granted Critical
Publication of DK0572537T3 publication Critical patent/DK0572537T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK92907362T 1991-02-19 1992-02-18 Cytokinnhibitorer DK0572537T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65757891A 1991-02-19 1991-02-19
PCT/US1992/001283 WO1992014462A1 (en) 1991-02-19 1992-02-18 Cytokine inhibitors

Publications (1)

Publication Number Publication Date
DK0572537T3 true DK0572537T3 (da) 2000-03-27

Family

ID=24637788

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92907362T DK0572537T3 (da) 1991-02-19 1992-02-18 Cytokinnhibitorer

Country Status (14)

Country Link
US (2) US5602166A (da)
EP (1) EP0572537B1 (da)
JP (1) JP3162071B2 (da)
KR (1) KR930702975A (da)
AT (1) ATE186641T1 (da)
AU (1) AU657745B2 (da)
CA (1) CA2104214C (da)
DE (1) DE69230314T2 (da)
DK (1) DK0572537T3 (da)
ES (1) ES2138595T3 (da)
GR (1) GR3032612T3 (da)
IE (1) IE920508A1 (da)
WO (1) WO1992014462A1 (da)
ZA (1) ZA921120B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9201803D0 (en) * 1992-01-28 1992-03-11 Smithkline Beecham Corp Methods
GB9201804D0 (en) * 1992-01-28 1992-03-11 Smithkline Beecham Corp Methods
GB9315306D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
GB9315340D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
GB9315351D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9414902D0 (en) * 1994-07-23 1994-09-14 Smithkline Beecham Corp Methods
BR9601909A (pt) * 1995-07-13 1999-10-13 Smithkline Beecham Corp N,n-dietil-8,8-dipropil-2-azaspiro(4,5)decano-2-propan amina dimaleato
WO1997002820A1 (en) * 1995-07-13 1997-01-30 Anormed Inc. N,n-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dimaleate
PL329931A1 (en) * 1996-05-17 1999-04-26 Anormed Inc Application of substituted azaspirane in treating asthma
GB2309167A (en) * 1997-05-10 1997-07-23 Anormed Inc The use of azaspiranes in the treatment of Alzheimer's disease
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
CO5190696A1 (es) * 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
US6184246B1 (en) 1999-07-30 2001-02-06 The United States Of America As Represented By The Secretary Of Agriculture Inhibition of cytokine production by polymethoxylated flavones
WO2002080970A1 (en) * 2001-03-23 2002-10-17 Regents Of The University Of California Method for inhibiting articular cartilage matrix calcification
US7674838B2 (en) * 2002-04-05 2010-03-09 Henkel Corporation Curable foam elastomeric compositions
US20050250801A1 (en) * 2003-03-10 2005-11-10 Kunwar Shailubhai Method of treating cancer with azaspirane compositions
US20100203146A1 (en) * 2009-02-09 2010-08-12 Callisto Pharmaceuticals, Inc. Intermittent dosing strategy for treating rheumatoid arthritis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes

Also Published As

Publication number Publication date
GR3032612T3 (en) 2000-05-31
JP3162071B2 (ja) 2001-04-25
US5900430A (en) 1999-05-04
DE69230314D1 (de) 1999-12-23
CA2104214C (en) 2004-04-27
IE920508A1 (en) 1992-08-26
AU1463392A (en) 1992-09-15
US5602166A (en) 1997-02-11
EP0572537B1 (en) 1999-11-17
JPH06505483A (ja) 1994-06-23
KR930702975A (ko) 1993-11-29
ATE186641T1 (de) 1999-12-15
DE69230314T2 (de) 2000-02-24
AU657745B2 (en) 1995-03-23
ES2138595T3 (es) 2000-01-16
ZA921120B (en) 1993-01-27
EP0572537A1 (en) 1993-12-08
CA2104214A1 (en) 1992-08-20
WO1992014462A1 (en) 1992-09-03
EP0572537A4 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
DK0572537T3 (da) Cytokinnhibitorer
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
DE69030189D1 (de) Hemmung des wachstums von tumoren durch blockade des protein-c-systems
NO983189L (no) Nye substituerte imidazolforbindelser
SE9704870D0 (sv) New pharmaceutical formulation I
MY131298A (en) 5-heteroyl indole derivatives
NO930509L (no) Lavdensitets broennsement som kan fjernes med syre, og metoder
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
CY1107545T1 (el) Μεθοδοι για την προκληση θανατου καρκινικων κυτταρων και υποχωρησης του ογκου
DK0912192T3 (da) Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden
DK0527879T3 (da) Synergistiske terapeutiske præparater og fremgangsmåder.
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
NO905090L (no) Interleukin-1-inhibitorer og fremgangsmaate til deres fremstilling.
NO925041D0 (no) Nye 2-sakkarinylmetylaryl- og aryloksyacetater som er nyttige som proteolytiske enzymerinhibitorer
ATE346041T1 (de) N-hydroxyformamid-derivate
IT8420506V0 (it) Dispositivo di regolazione e di posizionamento per una poltrona.
KR930702896A (ko) 종양괴사인자 억제제
FI962264A0 (fi) Tulehduksia aiheuttavan sytokiinin muodostumisen inhibiittori, joka käsittää polyprenyylin johdannaisia aktiivisena ainesosana
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
ES2078501T3 (es) Metodo para el tratamiento de la trombocitopenia y composiciones farmaceuticas utiles para el mismo.
DE69217221D1 (de) Hydrochinonderivate und diese enthaltende Antioxydantien sowie Tumorinhibitoren
DE69025337D1 (de) Tumor-nekrose-faktor-antagonist
MX9206135A (es) Metodos
ITRM910710A0 (it) Metodo per la determinazione del fattore di necrosi tumorale (tnf) in forma biologicamente attiva